- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07596810
Ketamine Added to Quadratus Lumborum Block for Pain Relief After Infant Pyeloplasty (KETA-QLB)
Ketamine As Adjuvant to Bupivacaine in Ultrasound Guided Quadratus Lumborum Block for Infants Undergoing Open Pyeloplasty
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Postoperative pain management in infants undergoing open pyeloplasty remains challenging because opioid use may be associated with adverse effects, including respiratory depression, nausea, vomiting, and delayed recovery. Regional anesthesia techniques, including ultrasound-guided quadratus lumborum (QL) block, may improve postoperative analgesia and reduce opioid requirements.
Ketamine has analgesic properties through N-methyl-D-aspartate (NMDA) receptor antagonism and has been investigated as an adjuvant to local anesthetics in regional anesthesia. However, evidence regarding its use as an adjuvant in ultrasound-guided QL block in infants undergoing pyeloplasty is limited.
This prospective randomized study aims to evaluate the effectiveness of adding ketamine to bupivacaine in ultrasound-guided QL block for infants undergoing open pyeloplasty. Forty infants aged 0-12 months scheduled for elective open pyeloplasty are randomized into two groups. One group receives ultrasound-guided QL block using bupivacaine 0.25% (0.5 mL/kg) combined with ketamine hydrochloride (1 mg/kg), while the control group receives bupivacaine 0.25% (0.5 mL/kg) alone.
The primary outcome measure is postoperative pain assessed using the CRIES pain scale during the first 24 hours after surgery. Secondary outcome measures include time to first rescue opioid administration, total postoperative opioid consumption, length of hospital stay, and occurrence of adverse events or complications.
This study seeks to determine whether ketamine may improve postoperative analgesia and reduce opioid requirements when used as an adjuvant to bupivacaine in pediatric regional anesthesia.
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Alexandria, Egypt
- Alexandria University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Infants aged 0 to 12 months
- Scheduled for elective open pyeloplasty
- Eligible for ultrasound-guided quadratus lumborum block
- Parent or legal guardian able to provide informed consent
Exclusion Criteria:
- Congenital heart disease
- Prematurity
- Mechanical ventilation dependence
- Contraindications to regional anesthesia
- Coagulopathy or bleeding disorders
- Local infection at the injection site
- Known allergy or hypersensitivity to ketamine, bupivacaine, or study medications
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Ketamine + Bupivacaine QL Block
Participants receive ultrasound-guided quadratus lumborum block using ketamine hydrochloride (1 mg/kg) combined with bupivacaine 0.25% (0.5 mL/kg) during open pyeloplasty.
|
Ketamine hydrochloride (1 mg/kg) added to bupivacaine 0.25% (0.5 mL/kg) administered by ultrasound-guided quadratus lumborum block during open pyeloplasty.
|
|
Aktiv komparator: Bupivacaine QL Block
Participants receive ultrasound-guided quadratus lumborum block using bupivacaine 0.25% (0.5 mL/kg) alone during open pyeloplasty.
|
Bupivacaine 0.25% (0.5 mL/kg) administered by ultrasound-guided quadratus lumborum block during open pyeloplasty.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Postoperative Pain Assessed by CRIES Pain Scale by the end of 24 hours after surgery
Tidsramme: 24 hours after surgery
|
Postoperative pain severity assessed using the CRIES pain scale during the first 24 hours after surgery.
Higher scores indicate greater pain severity.
|
24 hours after surgery
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to First Rescue Opioid Administration
Tidsramme: 24 hours after surgery
|
Time elapsed from completion of surgery to first administration of rescue opioid analgesia (intravenous fentanyl).
|
24 hours after surgery
|
|
Total Postoperative Opioid Consumption
Tidsramme: 24 hours after surgery
|
Total postoperative fentanyl consumption during the postoperative observation period.
|
24 hours after surgery
|
|
Length of Hospital Stay
Tidsramme: Until hospital discharge (approximately 1-3 days)
|
Duration of hospitalization measured in days following surgery.
|
Until hospital discharge (approximately 1-3 days)
|
|
Occurrence of Postoperative Complications
Tidsramme: 24 hours after surgery until discharge
|
Incidence of adverse events and complications related to the intervention or postoperative period.
|
24 hours after surgery until discharge
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Smerte
- Nevrologiske manifestasjoner
- Postoperative komplikasjoner
- Patologiske prosesser
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Smerter, postoperativt
- Multicystisk nyre dysplasi, bilateral
- Organiske kjemikalier
- Hydrokarboner
- Cyclohexanes
- Cycloparaffins
- Hydrokarboner, alicyklisk
- Hydrokarboner, syklisk
- Anilider
- Amides
- Anilinforbindelser
- Aminer
- Bupivakain
- Ketamin
Andre studie-ID-numre
- 0307848
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .